ReviewSeminars in hematology2020
Improving CAR T cell therapy by optimizing critical quality attributes.
Review in Seminars in hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas.Blood neoplasia · 2026Trial
- Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids.BMC medicine · 2026Article
- Cell therapy manufacturing at full clinical scale: enhancing the quality CAR-T cell therapy starting materials through massively parallel automated microfluidic cell sorting.Lab on a chip · 2026Article
- Review
- Multimodal profiling of CAR T cells against glioblastoma using a microengineered 3D tumor-on-a-chip model.Bioactive materials · 2026Article
- Outcomes of point-of-care manufactured CAR T cell therapy for B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma in Vietnam.Molecular therapy. Oncology · 2026Article
- Microfluidics for cell therapy and manufacturing in oncology and regenerative medicine.Lab on a chip · 2026Review
- Process Systems Engineering in Precision Medicine: Opportunities in Autologous CAR-T Therapy.Engineering in life sciences · 2026Review
- Chimeric antigen receptor dendritic cells suppress melanoma growth in preclinical cancer models.Journal for immunotherapy of cancer · 2025Article
- Breakthrough for Anticancer Immunotherapy: Current Advances in Manufacturing Protocols of Chimeric Antigen Receptor-Based Therapies.Antibodies (Basel, Switzerland) · 2025Review
- In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies.Experimental hematology & oncology · 2025Review
- Practice of Cryopreservation of Cellular Starting Materials from the Asia-Pacific Region: An Industrial Perspective.Therapeutic innovation & regulatory science · 2025Review
- Managing allorejection in off-the-shelf CAR-engineered cell therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- High-dimensional temporal mapping of CAR T cells reveals phenotypic and functional remodeling during manufacturing.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Identification of the conditions and minimum requirements necessary for the release of autologous fresh CAR T-cell products under hospital exemption: a position paper from the WP-bioproduction of the UNITC consortium.Bone marrow transplantation · 2025Article
- Establishing a GMP-compliant manufacturing process and phase-appropriate analytics for early development of a FiCAR T-cell product with a novel CAR spacer.Scientific reports · 2025Article
- Quality assessment strategy development and analytical method selection of GMP grade biological drugs for gene and cell therapy.BBA advances · 2025Review
- Current Non-Viral-Based Strategies to Manufacture CAR-T Cells.International journal of molecular sciences · 2024Review
- Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis.The Journal of clinical investigation · 2024Article
- Label-free ghost cytometry for manufacturing of cell therapy products.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Whether as a cure or bridge to transplant, chimeric antigen receptor (CAR)-T cell therapies have shown dramatic outcomes for the treatment of hematologic malignancies, and particularly relapsed/refractory B cell leukemia and lymphoma. However, these therapies are not effective for all patients, and are not without toxicities. The challenge now is to optimize these products and their manufacture. The manufacturing process is complex and subject to numerous variabilities at each step. These variabilities can affect the critical quality attributes of the final product, and this can ultimately impact clinical outcomes. This review will focus on optimizing the manufacturing variables that can impact the safety, purity, potency, consistency and durability of CAR-T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.